All accepted abstracts are available in the Journal for ImmunoTherapy of Cancer (JITC).

Abstract Titles

Poster Presentation Dates

All odd numbered posters will be presented on Wednesday, Nov. 11, from 5:15-5:45 p.m. EST and Friday, Nov. 13, from 4:40-5:10 p.m. EST. Even numbered posters will be presented on Thursday, Nov. 12, from 4:50-5:20 p.m. EST and Saturday, Nov. 14, from 1-1:30 p.m. EST.

Posters will be on display from 8 a.m. on Monday, Nov. 9, until the virtual poster hall closes on December 31, 2020.

#	Type	Title	Authors	Category	Keywords
362	Oral Presentation	A PhII study of bemcentinib, a first-in-class selective AXL kinase inhibitor, in combination with pembrolizumab in pts with previously-treated advanced NSCLC: Updated clinical & translational analysis	James Spicer, PhD, FRCP; Åslaug Helland, MD, PhD; Enric Carcereny, MD; Edurne Arriola, MD, PhD; Manuel Dómine Gomez, MD, PhD; Jose Manuel Trigo Perez, MD, PhD; Jonathan R. Thompson, MD; James Strauss, MD; Ana Laura Ortega Granados, MD; Enriqueta Felip, MD PhD; Emmett V. Schmidt, MD PhD; Michael J. Chisamore, PhD; Noelly Madeleine, PhD; Austin Rayford, MS; Katherine Lorens; Abdul Siddiqui, MD; Hani Gabra, MD, PhD, FRCP; Jaya Nautiyal, PhD; David Micklem, PhD; James B. Lorens, PhD; Matthew G. Krebs, MD, PhD;	In-Progress Clinical Trials	Antigen presenting cells; Biomarkers; Checkpoint blockade; Clinical study; Clinical trial; Regulatory T cell (Treg cell); Targeted therapy; Tumor evasion; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment